What is HC Wainwright’s Forecast for STOK FY2025 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at HC Wainwright increased their FY2025 EPS estimates for shares of Stoke Therapeutics in a report released on Tuesday, February 18th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($2.68) per share for the year, up from their previous estimate of ($2.82). HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($1.65) EPS, FY2028 earnings at ($0.73) EPS and FY2029 earnings at $0.45 EPS.

Several other analysts have also commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, February 18th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $23.00.

Stoke Therapeutics Stock Performance

STOK stock opened at $8.33 on Friday. The firm has a market cap of $441.24 million, a PE ratio of -3.97 and a beta of 0.95. The firm’s 50 day moving average price is $10.55 and its 200-day moving average price is $12.27. Stoke Therapeutics has a one year low of $5.21 and a one year high of $17.58.

Institutional Trading of Stoke Therapeutics

A number of large investors have recently modified their holdings of STOK. Toronto Dominion Bank purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth $35,001,000. RTW Investments LP grew its stake in shares of Stoke Therapeutics by 10.1% during the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after purchasing an additional 471,240 shares in the last quarter. Norges Bank acquired a new position in shares of Stoke Therapeutics during the fourth quarter worth $3,472,000. Tang Capital Management LLC acquired a new position in shares of Stoke Therapeutics during the fourth quarter worth $3,309,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Stoke Therapeutics during the fourth quarter worth $3,218,000.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the sale, the insider now owns 51,277 shares of the company’s stock, valued at approximately $618,913.39. This represents a 16.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jonathan Allan sold 13,666 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the sale, the general counsel now directly owns 21,476 shares in the company, valued at $292,288.36. This represents a 38.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock valued at $809,421 over the last quarter. 11.30% of the stock is owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.